MedPage Today is collecting stories of HHS staffers across all agencies affected by Trump administration cuts. If you want to ...

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

In addition, HHS Secretary Robert F. Kennedy Jr. addressed the delay in Novavax's approval in a CBS interview earlier this ...

Yahoo Finance host Julie Hyman takes a look at today's top moving stocks and biggest market stories in this segment of Market ...

Novavax said Monday morning that the Food and Drug Administration was asking the company to run a new trial of its Covid-19 ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

Novavax’s COVID-19 vaccine could soon receive full approval from the United States Food and Drug Administration.

Analysis found 25% tariff on pharmaceutical imports would hike U.S. drug costs by nearly $51 billion annually, boosting ...

After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.

Markets were also boosted by the prospect of a quieter geopolitical environment, as the US attempts to smooth the wrinkles in ...

A summary of current health news, including the disbanding of a U.S. Justice Department unit focusing on food and drug safety ...